Page last updated: 2024-09-04

lonafarnib and docetaxel anhydrous

lonafarnib has been researched along with docetaxel anhydrous in 3 studies

Compound Research Comparison

Studies (lonafarnib)	Trials (lonafarnib)	Recent Studies (post-2010) (lonafarnib)	Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)
224	34	90	12,110	3,216	6,920

Protein Interaction Comparison

Protein	Taxonomy	lonafarnib (IC50)	docetaxel anhydrous (IC50)
Kinesin-like protein KIF11	Homo sapiens (human)		0.0014
Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)		5.0119

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bishop, WR; Hajian, G; Liu, M; Nielsen, LL; Shi, B; Terracina, G; Yaremko, B	1
Bishop, WR; Hsieh, Y; Kirschmeier, P; Liu, G; Long, BJ; Marrinan, CH; Taylor, SA	1
Bender, L; Chanel-Vos, C; Escuin, D; Fanucchi, MP; Gal, A; Giannakakou, P; Harvey, RD; Kauh, J; Khuri, FR; Kutner, M; Marcus, A; Pan, L; Ramalingam, SS; Saba, N; Shin, DM	1

Trials

1 trial(s) available for lonafarnib and docetaxel anhydrous

Article	Year
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. Cancer, 2011, Sep-01, Volume: 117, Issue:17 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Piperidines; Pyridines; Taxoids	2011

Other Studies

2 other study(ies) available for lonafarnib and docetaxel anhydrous

Article	Year
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer chemotherapy and pharmacology, 2000, Volume: 46, Issue:5 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, Phytogenic; Cell Division; Docetaxel; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Male; Mice; Mice, Nude; Mice, Transgenic; Paclitaxel; Piperidines; Pyridines; Taxoids; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2000
Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. International journal of cancer, 2009, Dec-01, Volume: 125, Issue:11 Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms, Hormone-Dependent; Piperidines; Prostatic Neoplasms; Pyridines; Taxoids; Xenograft Model Antitumor Assays	2009

Article

Year

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.

Cancer chemotherapy and pharmacology, 2000, Volume: 46, Issue:5

Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, Phytogenic; Cell Division; Docetaxel; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Male; Mice; Mice, Nude; Mice, Transgenic; Paclitaxel; Piperidines; Pyridines; Taxoids; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2000

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.

International journal of cancer, 2009, Dec-01, Volume: 125, Issue:11

Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms, Hormone-Dependent; Piperidines; Prostatic Neoplasms; Pyridines; Taxoids; Xenograft Model Antitumor Assays

2009